Campaign successes

In 2024, Enhertu (a life-extending drug for HER2-low metastatic breast cancer) was rejected for use on the NHS for being too expensive.

After more than 2 years of relentless campaigning alongside METUPUK and Make 2nds Count, and the backing of over 385,000 people across two petitions, Enhertu was finally made available on the NHS in England in September 2026.

Screening finds most breast cancers early, when survival is almost 100%. But for 4 years in a row, the NHS haven't met its target for how many women should be screened for breast cancer in England.

With the support of over 55,000 campaigners, we successfully called on NHS England to deliver a national breast screening awareness campaign, to encourage more women to attend their appointment when invited.

We were worried that the government wasn’t doing enough to ensure people were diagnosed as quickly as possible.

That’s why we called on them to introduce a truly ambitious target for how long it should take for people to have breast cancer diagnosed or ruled out. Thanks to the campaign, hospitals are expected to give results within 28 days for over 90% of people who’ve been referred urgently.

For too long, women living with triple negative metastatic (secondary) breast cancer faced a lack of effective treatment options.

The drug, Trodelvy, offered women the potential of more time to live, but it was provisionally rejected for routine use on the NHS in England. Thanks to the backing of almost 115,000 people, we helped get the decision reversed and Trodelvy was approved.

In 2022, olaparib was provisionally rejected for use on the NHS in England.

Olaparib is a potentially life-saving primary breast cancer drug that could reduce the risk of cancer returning or progressing to incurable metastatic (secondary) breast cancer. Over 70,000 campaigners backed our call for it to be made available. Thanks to their support, olaparib was approved for routine use on the NHS in England in 2023, and the rest of the UK promptly followed suit.